Increasing O-GlcNAcylation levels by the OGA inhibitor, NButGTA, was shown to reduce Aβ40, Aβ42 peptides levels and plaque formation, resulting in cognition improvement in the 5xFAD mouse model of Alzheimer’s disease [70]. The gene discussed is OGA; the disease is Alzheimer disease.